GSA Capital Partners LLP cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 62.9% in the ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. While you may have an investing style you rely on, finding great stocks is made ...

Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow ... Momentum investors should take note of this Medical stock. ACAD has a Momentum Style Score of B, and shares are up 21.9% over ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

This cashed up ASX 200 share could rise strongly from current levels according to analysts at Bell Potter. Here's ...